

Roy S Gardner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5646545/publications.pdf>

Version: 2024-02-01

66
papers

7,908
citations

304602

22
h-index

123376

61
g-index

67
all docs

67
docs citations

67
times ranked

5488
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
2	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
3	Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. European Journal of Heart Failure, 2006, 8, 355-360.	2.9	174
4	The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. European Journal of Heart Failure, 2006, 8, 63-67.	2.9	113
5	UK guidelines for referral and assessment of adults for heart transplantation. Heart, 2011, 97, 1520-1527.	1.2	99
6	The "Ten Commandments" of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2022, 43, 440-441.	1.0	95
7	HeartLogic Multisensor Algorithm Identifies Patients During Periods of Significantly Increased Risk of Heart Failure Events. Circulation: Heart Failure, 2018, 11, e004669.	1.6	73
8	Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). European Heart Journal, 2014, 35, 2714-2721.	1.0	71
9	Non-ischæmic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart, 2018, 104, 144-150.	1.2	61
10	Which patients with heart failure should receive specialist palliative care?. European Journal of Heart Failure, 2018, 20, 1338-1347.	2.9	60
11	The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 2016, 18, 1491-1498.	2.9	54
12	Heart Failure Association of the <sc>European Society of Cardiology</sc> Specialist Heart Failure Curriculum. European Journal of Heart Failure, 2014, 16, 151-162.	2.9	52
13	The Emerging Potential of the Apelin-APJ System in Heart Failure. Journal of Cardiac Failure, 2015, 21, 489-498.	0.7	43
14	GuÃa ESC 2021 sobre el diagnÃstico y tratamiento de la insuficiencia cardiaca aguda y crÃnica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	0.6	40
15	Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials. JACC: Heart Failure, 2015, 3, 603-614.	1.9	36
16	A change in N-terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure. European Journal of Heart Failure, 2007, 9, 266-271.	2.9	34
17	Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. European Heart Journal, 2007, 28, 3027-3033.	1.0	30
18	N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor- α in patients referred for consideration of cardiac transplantation. European Journal of Heart Failure, 2005, 7, 253-260.	2.9	29

#	ARTICLE	IF	CITATIONS
19	Real-world evidence in a national health service: results of the UK CardioMEMS HF System Post-Market Study. <i>ESC Heart Failure</i> , 2022, 9, 48-56.	1.4	28
20	LGE and NT-proBNP Identify Low Risk of Death or Arrhythmic Events in Patients With Primary Prevention ICDs. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 561-569.	2.3	26
21	Ferumoxylol-enhanced magnetic resonance imaging in acute myocarditis. <i>Heart</i> , 2018, 104, 300-305.	1.2	24
22	Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. <i>Heart</i> , 2019, 105, 1325-1334.	1.2	24
23	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. <i>Circulation: Heart Failure</i> , 2015, 8, 717-724.	1.6	22
24	N-Terminal Brain Natriuretic Peptide, But Not Anemia, Is a Powerful Predictor of Mortality in Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2005, 11, S47-S53.	0.7	21
25	Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design. <i>ESC Heart Failure</i> , 2015, 2, 25-36.	1.4	21
26	Ambulatory Monitoring of Heart Sounds via an Implanted Device Is Superior to Auscultation for Prediction of Heart Failure Events. <i>Journal of Cardiac Failure</i> , 2020, 26, 151-159.	0.7	21
27	Ferumoxylol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3T. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 46.	1.6	20
28	Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2014, 35, 3426-3433.	1.0	18
29	Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 618-625.	1.9	18
30	Haemodynamic monitoring of cardiac status using heart sounds from an implanted cardiac device. <i>ESC Heart Failure</i> , 2017, 4, 605-613.	1.4	17
31	Who needs a heart transplant? The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> . <i>European Heart Journal</i> , 2006, 27, 770-772.	1.0	16
32	ICDs in end-stage heart failure. <i>BMJ Supportive and Palliative Care</i> , 2012, 2, 94-97.	0.8	16
33	Clinical characteristics and outcomes of patients with angina and heart failure in the <sc>CHARM</sc> (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Tj ETQq1 1 0.784314.rgBT/Overlock 10 T	1.4	16
34	The ease of use and reproducibility of the Alere, Heart Check System: a comparison of patient and healthcare professional measurement of BNP. <i>Biomarkers in Medicine</i> , 2014, 8, 791-796.	0.6	14
35	Multiparameter diagnostic sensor measurements during clinically stable periods and worsening heart failure in ambulatory patients. <i>ESC Heart Failure</i> , 2021, 8, 1571-1581.	1.4	13
36	Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 1253-1261.	2.9	12

#	ARTICLE	IF	CITATIONS
37	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography-tandem mass spectrometry-based urine analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 296-301.	1.4	12
38	Biomarkers of acute rejection following cardiac transplantation. <i>Biomarkers in Medicine</i> , 2014, 8, 815-832.	0.6	10
39	Who needs an implantable cardioverter-defibrillator? Controversies and opportunities after DANISH. <i>European Journal of Heart Failure</i> , 2018, 20, 413-416.	2.9	10
40	Novel biomarkers in heart failure: an overview. <i>Biomarkers in Medicine</i> , 2009, 3, 453-463.	0.6	8
41	B-type natriuretic peptides in heart failure. <i>Biomarkers in Medicine</i> , 2007, 1, 243-250.	0.6	7
42	An update on peripartum cardiomyopathy. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1155-1160.	0.6	7
43	Do plasma concentrations of apelin predict prognosis in patients with advanced heart failure?. <i>Biomarkers in Medicine</i> , 2014, 8, 807-813.	0.6	7
44	Real-world outcomes in cardiac resynchronization therapy patients: design and baseline demographics of the SMART Registry. <i>ESC Heart Failure</i> , 2021, 8, 1675-1680.	1.4	7
45	Emerging role of the apelin system in cardiovascular homeostasis. <i>Biomarkers in Medicine</i> , 2007, 1, 37-43.	0.6	5
46	Who Benefits From a Defibrillator? Balancing the Risk of Sudden Versus Non-sudden Death. <i>Current Heart Failure Reports</i> , 2018, 15, 376-389.	1.3	5
47	Multiparameter diagnostic sensor measurements in heart failure patients presenting with SARS-CoV-2 infection. <i>ESC Heart Failure</i> , 2021, 8, 4026-4036.	1.4	5
48	The hazards of brussels sprouts consumption at Christmas. <i>Medical Journal of Australia</i> , 2012, 197, 661-662.	0.8	4
49	Emerging biomarkers for heart failure: an update. <i>Biomarkers in Medicine</i> , 2014, 8, 833-840.	0.6	4
50	The prognostic value of anemia, right-heart catheterization and neurohormones in chronic heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 51-57.	0.6	3
51	Bridging to Heart Transplantation with 128 Days of Intra-aortic Balloon Pump Support. <i>American Journal of Medicine</i> , 2014, 127, e9-e10.	0.6	3
52	Ventricular Assist Devices as Rescue Therapy in Cardiogenic Shock After Subarachnoid Hemorrhage. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1440-1443.	0.7	3
53	Reducing the electrogram review burden imposed by insertable cardiac monitors. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 741-750.	0.8	3
54	The reign of the natriuretic peptides in patients with heart failure continues. <i>Biomarkers in Medicine</i> , 2008, 2, 437-439.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Deactivation of implantable cardioverterâ€“defibrillators at end of life. <i>Future Cardiology</i> , 2013, 9, 885-896.	0.5	2
56	When to consider an implantable cardioverter defibrillator following myocardial infarction?. <i>Heart</i> , 2015, 101, 1996-2000.	1.2	2
57	Use of direct oral anticoagulants in thromboembolic disease. <i>The Prescriber</i> , 2016, 27, 15-22.	0.1	2
58	Thirty years of heart failure. <i>European Heart Journal</i> , 2018, 39, 824-826.	1.0	2
59	Ferumoxytol-enhanced MRI in patients with prior cardiac transplantation. <i>Open Heart</i> , 2019, 6, e001115.	0.9	2
60	Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic Point-of-Care Setting Compared With an Established Laboratory Reference Method. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961989042.	0.7	2
61	Interventricular lead separation is critical for NT-proBNP reduction after cardiac resynchronization therapy. <i>Biomarkers in Medicine</i> , 2014, 8, 797-806.	0.6	1
62	Biomarkers in mechanical circulatory support. <i>Biomarkers in Medicine</i> , 2014, 8, 855-869.	0.6	1
63	Can we use B-type natriuretic peptides to monitor patients with heart failure?. <i>Biomarkers in Medicine</i> , 2007, 1, 349-353.	0.6	0
64	Nongenetic markers in heart failure. <i>Biomarkers in Medicine</i> , 2014, 8, 773-775.	0.6	0
65	Pharmacological secondary prevention of MI. <i>The Prescriber</i> , 2021, 32, 13-20.	0.1	0
66	Chronic heart failure: epidemiology, investigation and management. <i>Medicine</i> , 2022, , .	0.2	0